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Abstract 
Cytochrome P450 (CYP) monooxygenases, the nature’s most versatile biological catalysts have unique ability to 
catalyse regio‑, chemo‑, and stereospecific oxidation of a wide range of substrates under mild reaction conditions, 
thereby addressing a significant challenge in chemocatalysis. Though CYP enzymes are ubiquitous in all biologi‑
cal kingdoms, the divergence of CYPs in fungal kingdom is manifold. The CYP enzymes play pivotal roles in various 
fungal metabolisms starting from housekeeping biochemical reactions, detoxification of chemicals, and adaptation 
to hostile surroundings. Considering the versatile catalytic potentials, fungal CYPs has gained wide range of attraction 
among researchers and various remarkable strategies have been accomplished to enhance their biocatalytic proper‑
ties. Numerous fungal CYPs with multispecialty features have been identified and the number of characterized fungal 
CYPs is constantly increasing. Literature reveals ample reviews on mammalian, plant and bacterial CYPs, however, 
modest reports on fungal CYPs urges a comprehensive review highlighting their novel catalytic potentials and func‑
tional significances. In this review, we focus on the diversification and functional diversity of fungal CYPs and recapitu‑
late their unique and versatile biocatalytic properties. As such, this review emphasizes the crucial issues of fungal CYP 
systems, and the factors influencing efficient biocatalysis.
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Background
Cytochrome P450 (CYP) monooxygenases, the ubiqui-
tous enzymes with catalytic versatility, substrate diversity 
and atypical kinetics are one of the most fascinating tar-
gets for biocatalysis and play diverse roles in biotechnol-
ogy, medicine and bioremediation [1–3]. The tetrapyrrole 
heme-thiolate CYP enzymes can catalyse the conver-
sions of various hydrophobic as well as lipophilic com-
pounds to more hydrophilic products in the presence 
of oxygen and cofactor NAD(P)H with or without an 
electron transfer system. Indeed, CYP enzymes are cer-
tainly the nature’s most versatile and promising catalysts 
[1, 4] owing to their varied and multifunctional charac-
teristics: (a) CYPs are structurally diverse and function-
ally versatile enzymes that can perform rate-limiting and 
irreversible reactions in biosynthetic pathways, (b) CYPs 
catalyze the regiospecific and stereospecific oxidation of 
non-activated hydrocarbons, which is intricate to accom-
plish through chemocatalysis, and (c) CYPs are unique 
chemoselective and enantioselective enzymes involved 
in the production of high-value products [5–8]. Hitherto, 
various aspects of CYPs have been extensively reviewed, 
including its evolutionary paths, structure and function, 
complexity and diversity of CYP reactions, biological var-
iations of electron transport chains, synthetic and cata-
lytic applications, and the regulation and engineering of 
CYP systems [5–13].
CYP superfamily of enzymes exist in all biological 
domains and their presence predates the emergence of 
oxygen-metabolizing life forms [14]. Interestingly, the 
divergence of CYPs in fungal kingdom is enormous, and 
are involved in the synthesis of a wide range of primary 
and secondary metabolites, as well as in the degradation 
of environmental pollutants [15, 16]. Being a ubiquitous 
organism, fungi inhabitants diverse ecological niches, 
and adapts to various sources of carbon and nitrogen for 
their survival and metabolism [15]. Recent study based 
on high-throughput sequencing reveals that about 5.1 
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million fungal species exist on earth, which is about 6 
times the total number of plant species [17]. Compre-
hensive biochemical analysis of molecular mechanisms 
showed that fungal adaptions are often facilitated by 
CYP monooxygenases [15]. Fungal CYPs play an essential 
role in their adaptations to ecological niches due to their 
diverse roles in the production of metabolites critical for 
pathogenesis, detoxification of xenobiotics and exploita-
tion of substrates [15, 16]. In recent decades, fungal CYPs 
have emerged as a revolutionary system and have gained 
widespread attention for biocatalysis due to their fasci-
nating and extraordinary metabolic diversity. While their 
distinguished role in primary and secondary metabolite 
synthesis fascinates biochemists and enzymologists, their 
xenobiotic detoxification and degradation properties 
captivates pharmacologists and toxicologists.
Although CYPs have been extensively reviewed [5–12], 
the limited number of reviews on fungal CYPs [15, 16, 
18] calls for an updated article to highlight novel and 
crucial findings. We comprehensively summarized the 
outlooks of fungal CYPs in terms of divergence, clas-
sification, electron transport system, and their recent 
advancements. A compilation of novel fungal CYPs and 
their functional significances with respect to versatile 
biocatalytic potentials has been explicated. Furthermore, 
we elaborate on critical parameters involved in the heter-
ologous expression and optimization of CYPs for efficient 
biocatalysis.
Divergence of fungal CYPs
Evolution of CYPs corresponds to the organismal adapta-
tion to diverse ecological niches, and the chemical war-
fare in synthesizing/neutralizing toxic metabolites among 
biological kingdoms [14]. The distinctive feature of fungi 
to survive on harsh environmental conditions, its extraor-
dinary defense mechanic systems and their ability to pro-
duce a wide variety of primary and secondary metabolites 
has mainly contributed to the evolution and diversification 
of fungal CYPs. Apparently, the divergence of CYPs in the 
fungal kingdom is manifold compared to other biological 
kingdoms, leading to a tremendous diversification of CYPs 
to meet the metabolic needs [9, 15, 16, 18]. In general, the 
genome size of fungi is smaller than in plant and animal 
kingdoms ranging from 8.97 to 177.57 mb [19]. Although, 
the average genome size of ascomycota and basidiomy-
cota species are 36.91 and 46.48  mb, respectively [19], 
the ratio of CYPs and open reading frames can vary from 
0.04  % (Saccharomyces cerevisiae) to 2.06  % (Postia pla-
centa) (Table 1). Fungal genome-sequencing projects have 
revealed the existence of >6000 fungal genes that code for 
putative CYPs, which yet have to be explored for novel cat-
alytic enzymes [15, 16, 20]. To date, a vast number of CYPs 
have been identified in >2500 fungal species, and these are 
classified into ≈400 CYP families (namely CYP51-CYP69, 
CYP501-CYP699, and CYP5001-CYP6999) [21, 22]. 
Indeed, fungi comprise the largest number of CYP fami-
lies/subfamilies, far outnumbering other kingdoms such 
as bacteria (333 CYP families), plants (127 CYP families), 
vertebrates (19 CYP families), and insects (67 CYP fami-
lies), reflecting the enormous evolutionary and functional 
diversity of CYPs in the fungal kingdom [23]. Interestingly, 
certain fungal species such as P. placenta (353 CYPs) also 
possess the highest CYP counts (Table  1), as compared 
with species in other domains, namely Mus musculus (102 
CYPs), Anopheles gambiae (105 CYPs), and Streptomyces 
avermilitis (33 CYPs), with the exception of plants (Oryza 
sativa, 455 CYPs) [2].
Nevertheless, the extraordinary functional and evolu-
tionary diversity of fungal CYPomes has complexified the 
classification of fungal CYPs. The classification of CYPs 
is generally based on their amino acid sequence similar-
ity, i.e., sequences with >40 % similarity form a single CYP 
family and sequences with >55 % similarity form subfami-
lies [24]. Remarkably, despite their wide diversity and low 
sequence similarities, fungal CYPs possess four signature 
motifs, along with their preserved tertiary structures and 
enzymatic functions, that facilitate the identification of 
CYPs from the fungal genome: (i) FXXGXRXCXG, the 
heme-binding domain enclosing the invariant Cys ligand 
to the heme; (ii and iii) motifs EXXR and PER, which 
form the E-R-R triad retains the position of heme pocket 
and stabilizes the core structure; and (iv) AGXDTT, the 
oxygen-binding and activation domain [14, 25–27]. Nev-
ertheless, despite the widely recognized conservative-
ness, the motifs are distinguishable among the taxonomic 
groups, and the most clear distinction was observed in 
prokaryotes, probably due to the early evolutionary diver-
gence [22]. Recent investigations of the 47 completed 
fungal genomes suggest that the two large gene duplica-
tions and the horizontal gene transfer in Ascomycota and 
Basidiomycota contributes to the diversification of fun-
gal CYP superfamily [22]. Apparently, despite their high 
divergence, fungal CYPs can be clustered into 15 clades 
based on their phylogenetic relationships [22]. This work 
provides clear insights into the evolutionary scenario of 
fungal CYP superfamily based on their phylogenetic and 
taxonomic relationships [28]. Interestingly, the highly 
conserved and consistent CYP51 and CYP61 global fami-
lies act as molecular clocks and specifies the individuali-
zation of CYPomes in the fungal kingdom [21].
CYP catalytic cycle and fungal CYP systems
CYPs catalyse the monooxygenase reaction (RH + O2 +  
2e− +  2H+ →  ROH +  H2O) by the insertion of one of 
the atoms of molecular oxygen into the substrate, while 
the second oxygen atom is reduced to water [9, 29]. 
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CYP-catalyzed substrate hydroxylation follows a gen-
eral catalytic mechanism (Fig.  1): (a) ‘substrate binding’ 
is the first process in the catalytic cycle, where the sub-
strate (RH) enters the active site and binds to the heme 
iron of CYP, which is in the oxidized state (Fe3+); (b) the 
‘first reduction step’ involves the transfer of one-electron 
to the ferric heme iron (Fe3+) by cytochrome P450 reduc-
tase (CPR), followed by the binding of molecular oxygen, 
thereby reducing it to form the ferrous dioxy complex 
(Fe2+–O2); (c) the ‘second reduction step’ involves the 
transfer of the second electron and a proton either from 
the CPR or from cytochrome b5 (Cyt b5) yielding a fer-
ric hydroperoxy complex (Fe3+–OOH); (d) heterolytic 
cleavage of the O–O bond and the second protonation 
accompanied by the generation of a H2O molecule forms 
the reactive ferryl-oxo intermediate (Fe4+=O, porphy-
rin π-cation radical); (e) in the ‘product formation’ step, 
abstraction of a H2 atom followed by the radical recombi-
nation results in the formation of the hydroxylated prod-
uct (ROH); and (f ) the final step is dissociation of the 
oxidized substrate from the active site of CYP, wherein 
the enzyme returns to its initial ferric state (Fe3+) and 
is thus equipped to react again. An alternative route is 
binding of H2O2 to the ferric heme iron, which leads to 
the peroxide shunt pathway [5, 30].
With regard to the aforementioned catalytic process, 
CYPs employ highly diversified redox chains for the 
electron transfer mechanism. Depending on the topol-
ogy of the protein components involved in electron 
transfer, CYP systems are classified into 10 different 
classes, and the fungal CYPs fall into classes II, VIII, 
and IX systems [13, 16]. Class II comprises two inte-
gral membrane proteins: CYP and CPR containing the 
prosthetic cofactors FAD and FMN, which deliver two 
electrons from NAD(P)H to the heme moiety (Fig.  1). 
Alternatively, it may also comprise a third protein com-
ponent, Cyt b5, which transfers a second electron to 
the oxyferrous CYP. Rarely, certain CYPs (CYP5150A2) 
can be directly activated by Cyt b5 and NADH-depend-
ant Cyt b5 reductase (CB5R) in the absence of CPR 
[31]. Most of the fungal CYPs belong to class II and 
perform extremely diverse catalytic reactions (Fig.  2). 
Table 1 Representative distribution of putative CYPs and CPRs across fungal phyla
The genomic information is obtained from the genome browser in NCBI (http://www.ncbi.nlm.nih.gov/genome/browse/). The data information on ORFs and putative 
CYPs were obtained from fungal cytochrome P450 database (http://p450.riceblast.snu.ac.kr/species.php) and Dr. Nelson’s cytochrome P450 database (http://drnelson.
uthsc.edu/fungal.genomes.html), and information on putative CPRs was obtained from Ref. [78]
ORF open reading frame, NA information not available
Fungal Phyla Species Genome  
size (Mb)






Ascomycota Pezizomycotina Magnaporthe oryzae 45.0965 11,069 107 0.97 1
Neurospora crassa 41.1024 9935 43 0.43 1
Aspergillus fumigatus 29.385 9887 77 0.78 2
Aspergillus oryzae 37.1178 12,063 163 1.35 2
Aspergillus niger 34.8533 11,200 154 1.38 2
Aspergillus nidulans 30.2427 10,568 120 1.14 2
Cochliobolus lunatus 35.4974 NA NA NA 2
Fusarium graminearum 36.6676 13,339 118 0.88 3
Fusarium oxysporum 61.4707 17,735 169 0.95 4
Fusarium verticillioides 41.8851 14,199 129 0.91 1
Penicillium chrysogenum 32.5255 12,791 101 0.79 NA
Saccharomycotina Saccharomyces cerevisiae 14.2673 6692 3 0.04 1
Candida albicans 27.5589 6090 10 0.16 1
Candida tropicalis 15.3268 6258 12 0.19 1
Yarrowia lipolytica 20.6238 6524 17 0.26 1
Taphrinomycotina Schizosaccharomyces pombe 12.5913 5058 2 0.04 1
Basidiomycota Agaricomycotina Phanerochaete chrysosporium 29.8426 10,048 145 1.44 1
Postia placenta 90.8919 17,173 353 2.06 NA
Pucciniomycotina Puccinia graminis 88.7244 20,567 18 0.09 1
Ustilaginomycotina Ustilago maydis 19.6644 6689 22 0.33 NA
Zygomycota Rhizopus oryzae 47.5346 17,482 49 0.28 2
Phycomyces blakesleeanus 53.9 14,792 56 0.38 NA
Chytridiomycota Batrachochytrium dendrobatidis 24.3151 8732 9 0.1 NA
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Interestingly, in the class VIII, fungi encompass fused 
proteins in which the N-terminal heme domain is fused 
with a C-terminal diflavin reductase partner (CPR) via 
a short protein linker (P450foxy) [32]. Herein, the elec-
trons are transferred from NADPH to the active site of 
CYP through its reductase domain. Class VIII CYPs are 
catalytically self-sufficient and perform subterminal 
hydroxylation of fatty acids, closely resembling a bac-
terial CYP (P450BM3) (Fig.  2). Exceptionally, class IX 
is composed of single protein, whereby electrons are 
directly transferred from NAD(P)H to CYP without the 
need for any additional redox partners (P450nor) [32]. 
Class IX differs functionally from the rest of the CYPs 
because they catalyze the reduction of two molecules 
of NO to N2O. Interestingly, P450nor is the only solu-
ble fungal CYP discovered so far, and performs denitri-
fication (Fig. 2).
Functional diversity of fungal CYPs
In the fungal kingdom, CYPs are involved in the bio-
synthesis of various primary and secondary metabolites 
with high substrate specificity. Some notable examples of 
the fungal primary metabolism are housekeeping func-
tions such as ergosterol biosynthesis, meiotic spore-wall 
biogenesis, and n-alkane hydroxylation, whereas fun-
gal secondary metabolism deals with the biosynthesis of 
hormones, mycotoxins, and the like (Fig. 2) [16]. Fungal 
CYPs are also capable of detoxifying and degrading vari-
ous xenobiotic compounds encountered in their environ-
ments, such as polycyclic aromatic hydrocarbons (PAHs), 
phenolic compounds, and other toxic environmental 
pollutants [16]. There have been ample studies regarding 
fungal CYP-mediated reactions, and these reports have 
been reviewed [16]. In recent years, the discovery of sev-
eral novel fungal CYPs has further expanded the scope of 
their biotechnological and industrial applications. Some 
of the exceptional and versatile reactions of fungal CYPs 
will be described in this review and are structurally illus-
trated (Fig. 3).
One of the well-studied fungal CYPs is the omnipo-
tent CYP51 enzyme responsible for oxidative removal of 
the 14α methyl group of eburicol and lanosterol to form 
∆14,15-desaturated intermediates. Interestingly, in con-
trast to the general fungal CYP51 enzymes, MgCYP51 
from Mycosphaerella graminicola demonstrated selec-
tivity, sterol specificity, and temperature sensitivity by 
demethylating only eburicol, but not lanosterol at low 
temperatures (22  °C) [33]. Advances in this area have 
been crucial in the development of azole-based anti-
fungal drugs targeted towards CYP51 enzyme, which 
inhibits ergosterol biosynthesis and causes disrup-
tion of cell membrane [34, 35]. However, the develop-
ment of resistance by fungal species, and the metabolic 
similarities within the fungal kingdom as well as higher 
eukaryotes constraints the effective treatment against 
fungal infections [36]. Strikingly, CYP53 emerges as 
an ideal target for the development of more selective 
antifungal treatment, as this homolog is native only to 
pathogenic fungi and it plays crucial roles in both fun-
gal primary (β-ketoadipate pathway) and secondary 
metabolism (detoxification of phenolic compounds) [36, 
37]. Though the sole CYP53 metabolism is through the 
Fig. 1 CYP catalytic cycle and schematic representation of the interaction of CYP‑CPR for class II CYP system
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benzoate-para-hydroxylation, the substrate specificity 
of CYP53 enzymes may vary among fungal (ascomyce-
tous and basidiomycetous) species [37–39]. Interest-
ingly, CYP53A19 of Fusarium oxysporum performs the 
hydroxylations of benzoic acid and 3-hydroxybenzoic 
acid (converted into 1) (Fig.  3a), as well as the dem-
ethylation of 3-methoxybenzoic acid [38]. In con-
trary to the general hypothesis that CYP53 exhibits 
enzyme-substrate binding only towards the carboxyl 
group of benzoate derivatives, it is worth mentioning 
that CYP53 also shows substantial specificity towards 
methoxyl group (s) in the stilbene derivatives [40]. In 
P. placenta, CYP53D2 performs the O-demethylation 
activity against 3,5,4′-trimethoxy-trans-stilbene and 
3,5-dimethoxy-trans-stilbene to produce 3-hydroxy-
5,4′-dimethoxy-trans-stilbene and 3,5-dihydroxy-4′-
methoxy-trans-stilbene, respectively (2) [40].
Terminally oxidized omega hydroxy fatty acids 
(ω-OHFAs) are multifunctional compounds involved 
in the production of various industrial products with 
Fig. 2 Representative scheme of functional diversification and classification of fungal CYP systems. Categorization of the functional properties of 
Class II CYP systems based on the primary metabolism, secondary metabolism and xenobiotic detoxification was perceived from Ref. [16]
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broad commercial and pharmaceutical implications [41]. 
However, due to the selectivity and controlled reactiv-
ity in C-H oxygenation reactions, the chemosynthesis of 
ω-OHFAs is intricate to accomplish. Interestingly, fun-
gal CYPs are involved in the initial and rate limiting step 
of hydroxylation of n-alkanes and fatty acids [42, 43]. 
In Starmerella bombicola, members of the CYP52 fam-
ily (CYP52M1, CYP52E3, and CYP52N1) performed the 
ω- and ω-1 hydroxylation of various fatty acids (3) [44]. 
CYP52M1 is involved in biosynthesis of sophorolipid, 
Fig. 3 Versatile monooxygenase reactions catalysed by fungal cytochrome P450 enzymes. a Selected examples of reaction products of fungal 
CYPs. b Selected examples of multifunctional reactions of fungal CYPs. The products were generated through multiple consecutive catalytic reac‑
tion mediated by a single CYP. Newly introduced hydroxyl groups and bonds are shown in red
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whereas CYP52E3 and CYP52N1 might be involved in 
the alkane metabolism [44]. Members of the CYP52 fam-
ily have also been identified in the entomopathogenic 
fungi Metarhizium robertsii (MrCYP52) and Beauve-
ria bassiana (CYP52X1) and are primarily involved in 
alkane and insect epicuticle degradation [45, 46]. In 
F. oxysporum, CYP539A7 catalyzes the regioselective 
hydroxylation at the ɷ-position of caprylic (4), capric, 
and lauric acid, whereas CYP655C2 was reactive only 
towards capric and lauric acid [41]. Correspondingly, 
CYP630B18 from Grosmannia clavigera performs the 
highly specific ω-hydroxylation towards oleic acid [47]. 
Fungal CYPs are also involved in the hydroxylation of fla-
vonoids, a significant secondary metabolite with a wide 
range of potential pharmacological applications [48, 49]. 
In P. chrysosporium, CYP65A2 catalyzes the 3′-hydroxy-
lation of naringenin to yield eriodictyol (5) [48], whereas 
CYP50C (CYP5147A1) and CYP142C (CYP5136A1) cat-
alyze the 3′-hydroxylation of flavone (6) and O-deethyl-
ation of 7-ethoxycoumarin [49]. In A. oryzae, CYP57B3 
converts the isoflavonoid genistein into 8-hydroxy- (7), 
6-hydroxy-, and 3′-hydroxy-genistein [50].
Remarkably, certain fungal CYPs (CYP5136A2, 
CYP5145A3, CYP5144A7, CYP5136A3, CYP5142A3, 
and CYP5144A5) have an extraordinary capability to 
degrade and/or mineralize the recalcitrant PAHs [51]. 
In P. chrysosporium, CYP63A2 and CYP5136A3 oxidize 
structurally diverse hydrocarbons such as fused-ring 
high-molecular-weight PAHs (8), endocrine-disrupt-
ing long-chain alkylphenols (9), and crude oil aliphatic 
hydrocarbon n-alkanes [52, 53]. In addition, CYP mem-
bers of P. placenta (CYP5150, CYP5027, and CYP5350) 
are also involved in the oxidation of a series of PAHs 
such as anthracene, carbazole, phenanthrene, and pyr-
ene [40]. Interestingly, the chemically complex stereo- 
and regioselective hydroxylation steps involved in the 
production of steroid drugs are performed by certain 
filamentous fungi mediated by CYP enzymes [54]. In 
Rhizopus oryzae, CYP509C12 performed steroid hydrox-
ylation at the 11α and 6β positions towards various sub-
strate spectra, including progesterone, testosterone, 
11-deoxycorticosterone, and 11-deoxycortisol (10) [55]. 
Furthermore, members of CYP512 along with CYP5139 
and CYP5150 from P. placenta also showed substantial 
reactivity towards steroidal compounds, primarily tes-
tosterone [40]. Recently, CYPs capable of performing 
complex regioselective and stereoselective bimolecular 
phenoxy radical couplings have been identified in fungi. 
The bicoumarin synthase CYPs KtnC (from Aspergillus 
niger) and DesC (from Emericella desertorum) performed 
the regio- and stereoselective biaryl coupling of the same 
monomeric coumarin 7-demethylsiderin and formed 
the 8,8′-dimer P-orlandin (11) and M-desertorin A (12), 
respectively [56].
Fungal CYPs also appear as multifunctional biosyn-
thetic enzymes performing consecutive multiple catalytic 
processes, which differ from their substrate promiscuity 
or broad substrate specificity (Fig.  3b). F. fujikuroi har-
bor four multifunctional CYPs (CYP68A1, CYP68B1, 
CYP69A1, and CYP503A1) and performs 10 of the 15 
biosynthetic steps towards the production of gibberel-
lins [57]. In F. verticillioides, CYP505 (Fum6) is involved 
in the two consecutive hydroxylation reactions at car-
bons C-14 and C-15 for the synthesis of fumonisin pol-
yketide [58]. Similarly, in F. graminearum, CYP58 (Tri4) is 
involved in the four consecutive oxygenation steps from 
trichodiene (13) to isotrichotriol (14) (one epoxidation 
and three hydroxylations) towards trichothecene skeleton 
formation [59]. In A. terreus during the biosynthesis of 
terretonin, the CYP enzyme Tri6 catalyzes three succes-
sive oxidations to transform terrenoid (15) into an unsta-
ble intermediate (16) [60]. Similarly, during the lovastatin 
biosynthesis in A. terreus, LovA performed two central 
consecutive oxidations (introduction of 4α,5-double bond 
and C-8 hydroxylation), in which LovA catalyzed the 
conversion of dihydromonacolin L acid (17) to monaco-
lin L acid and then to monacolin J acid (18) [61, 62]. Fur-
thermore, in A. fumigatus, the biosynthetic gene cluster 
involved in the fumagillin biosynthetic pathway encom-
passes a multifunctional Fma-P450 (Af510), which per-
forms successive hydroxylations, bicyclic ring-opening, 
and two epoxidations to convert β-trans-bergamotene 
(19) into 5-keto-demethoxyfumagillol (20) [63]. Inter-
estingly, fungal kingdom encompasses an allied group of 
CYP like heme proteins, unspecific peroxygenases (UPO, 
EC1.11.2.1), performing peroxide-driven substrate oxi-
dation [64]. It combines the catalytic cycle of heme per-
oxidases with the “peroxide shunt” pathway of CYPs, and 
prefers H2O2 over NAD(P)H. Some of the notable fungal 
peroxygenases are AaeUPO, CraUPO and MroUPO, and 
are involved in the oxidation of halides, aryl alcohols, 
naphthalene, bromide as well as bulkier substrates [64]. 
Furthermore, fungi also possess self-sufficient and func-
tionally linked DOX-CYP fusion enzymes. Herein, the 
N-terminal dioxygenase (DOX) domains are homologs 
to animal heme peroxidases, and their C-terminal CYP 
domains functions on peroxide shunt pathway [65]. The 
fungal DOX-CYP gene family has five subfamilies and 
recently a new member of 10R-DOX-EAS (MGG_10859) 
capable of performing epoxy alcohol synthase activities 
was identified in Magnaporthe oryzae [65]. Although 
these group of enzymes are slightly different from clas-
sic CYP enzymes, it is worth mentioning their functional 
properties for further comprehensive analysis.
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Systematic approach to heterologous expression 
of fungal CYPs
In order to explore the enzymatic, structural and func-
tional characteristics of fungal CYPs, the heterologous 
expression of enzymes is often required. Microbial cells 
serves as an excellent factories for heterologous enzyme 
production, representing about 90  % of the total bio-
transformation market [66]. Crucial for achieving their 
functional expression is the identification of an appro-
priate host, since handling fungal CYPs can be rather 
tricky because of their membrane-bound nature, low 
expression levels, protein instability, effective substrate 
uptake and tolerance and need for rich electron trans-
fer cofactors [7]. In addition, the primary challenge in 
amplifying full-length cDNA is to determine appropriate 
mRNA profiles due to the existence of introns in the fun-
gal DNA. In general, the expression of fungal CYP genes 
involved in secondary metabolite synthesis is rather com-
plex and are mainly influenced by culture conditions 
[67]. Indeed, some of the fungal CYP-encoding genes 
are independently regulated and differentially expressed; 
several CYPs may be induced upon different xenobiotic 
aromatic and aliphatic compounds at the transcriptional 
level [51]. In P. chrysosporium, six PAH-responsive CYP 
genes identified by genome-wide microarray screen-
ing were induced and upregulated upon varying ring-
sized PAHs, and their catalytic function towards various 
PAHs was determined using recombinant enzymes [51]. 
Furthermore, the induction of CYPs by pentachloro-
phenol (PCP) was also observed in P. chrysosporium, 
in which only the PCP-induced fungal microsomes led 
to the oxidation of PCP to form tetrachlorohydroqui-
none [68]. Remarkably, the transcriptional regulation of 
CYP-dependent metabolic pathways can be alternatively 
induced or upregulated by defined high or low nitrogen 
conditions, as observed in P. chrysosporium, C. versicolor, 
P. placenta, and A. oryzae [40, 69, 70]. Moreover, as fun-
gal CYPs follow a time-dependent course of gene expres-
sion, the use of RNA cocktail mixtures isolated from 
different culture intervals (5–20  days) has proved to be 
successful for obtaining cDNA [38, 41, 69, 70]. The fol-
lowing sections will elaborate on the various microbial 
cell factories towards efficient functional expression and 
potential biocatalysis of fungal CYPs.
Expression of fungal CYPs in bacterial host systems
Escherichia coli is the preferred bacterial host for het-
erologous protein expression due to its various advan-
tages such as high growth rate, cost-effective culture 
media, potential for high cell density, ease in genetic 
manipulation and extensive knowledge on its genetics 
and physiology [71]. Besides, unlike other bacteria (e.g., 
Streptomyces), E. coli does not possess any native CYP 
that could interfere with the measurement of overex-
pressed CYPs. However, since most heterologous CYPs 
are expressed as apoproteins in E. coli, a heme precursor, 
5-aminolevulinic acid, is supplemented during the induc-
tion of CYP or glutamyl-tRNA reductase, a key enzyme 
catalysing the rate-limiting reaction in heme biosynthe-
sis, is often co-expressed [72]. Generally, E. coli is the 
ideal host for soluble bacterial CYPs because it permits 
substantial protein expression and purification. How-
ever, the expression of membrane-bound eukaryotic 
fungal CYPs often suffers in bacterial systems as a result 
of non-expression, protein misfolding, or aggregation 
into insoluble inclusion bodies, as well as slow substrate 
uptake and lack of compatible reductase systems [37, 38, 
73]. For instance, bacterial expression of CYP52A21 from 
Candida albicans resulted in no detectable CYPs in the 
soluble fraction [74]. Nevertheless, an anionic surfactant, 
CHAPS, facilitated the solubilization of active CYP pro-
tein from the membrane fraction with 60  nmol/L of 
expression (Table  2) [74]. Several approaches to over-
express membrane bound CYPs in E. coli already were 
proved to be efficient, such as N-terminal modifications, 
chaperonin co-expression, and artificial gene synthesis 
with optimized codon frequency [73]. However, most of 
the studies were carried out with mammalian CYPs, and 
only a few studies focused on fungal CYPs. Although, 
the truncation/modification of N-terminal transmem-
brane domain (TMD) resolves the problems associated 
with hydrophobicity, the approach turned out to be case-
sensitive only improving expression of limited number 
of fungal CYPs [75]. One such example was recently 
observed for CYP53A19 of F. oxysporum, where the trun-
cation of the TMD region did not facilitate soluble pro-
tein expression and resulted in inactive CYP form [38].
Extensive heterologous expression of fungal CYP 
isoforms from P. chrysosporium and P. placenta were 
attempted using an E. coli expression system [75]. Among 
the 304 CYP isoforms studied, 27 CYPs were expressed 
in active form with/without deletion of the N-terminal 
hydrophobic domain, with the expression levels of some 
CYPs over 1000  nmol/L (Table  2) [75]. Currently, sev-
eral approaches exist to improve the bacterial expression 
of fungal CYPs, and one such promising approach is the 
construction of chimeric CYPs [76]. To this end, the dele-
tion and/or replacement of the hydrophobic N-terminal 
domains (NTD) acts as a membrane anchor to facili-
tate the bacterial expression of fungal CYPs [75, 76]. A 
large-scale screening identified 64 candidates including 
CYP5348N1, CYP5348T3P, CYP5144C1, CYP5144C8, 
and CYP5348L1v2, whose NTDs potentially increases 
the expression level of various CYPs in E. coli [76]. Espe-
cially, replacement of N-terminal amino acid sequences 
(M-S-L–L-L-A-A-T-L-F-L–H-S-R-Q-K-R-Y-P-L-) from 
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CYP5144C1 of P. chrysosporium promotes high-level 
expression for several fungal CYPs in bacterial sys-
tem [75, 76]. For example, a chimeric CYP5037E1v1 of 
P. placenta modified with the N-terminal sequence of 
CYP5144C1 enabled 2330  nmol P450/L of expression, 
about 10 times higher than the non-chimeric sequence 
[75, 76]. Additionally, codon optimization for proline 
residues in the proline-rich region (P–P–G–P) may also 
facilitate enhanced heterologous expression [76]. Fur-
thermore, factors such as reduction of secondary mRNA 
structures, bacterial codon usage, and vector and host 
strain selection, along with optimal culture conditions 
may also govern the bacterial expression of eukaryotic 
CYPs [73, 75, 76]. Despite various attempts to improve 
the overexpression of membrane-bound fungal CYPs in 
bacterial system, there is still no concrete theoretical and 
systematic approach, but improvements can be achieved 
only via trial-and-error process [76].
Expression of fungal CYPs in yeast host systems
The expression of fungal CYPs in yeast systems has 
gained widespread attention owing to the rich endoplas-
mic reticulum combined with the higher eukaryotic pro-
tein machinery [38, 41, 77, 78]. The conventional yeast 
S. cerevisiae is the most preferred microbial cell factory 
for extensive enzyme production as well as for synthesis 
of value added chemicals in industrial scales [79, 80]. S. 
cerevisiae serves as an ideal host system for eukaryotic 
CYP expression as it possesses three well-characterized 
CYPs, and enables the expression of membrane-bound 
CYP genes without any genetic modifications/trunca-
tions [38, 50, 77]. In addition, it offers conventional 
metabolic engineering approaches such as increasing the 
precursor supply by varying pathway enzyme expression 
levels or knocking out competing pathways to enhance 
the CYP mediated biocatalysis [41]. Functional studies 
of heterologously expressed CYPs using S. cerevisiae can 
be performed by three different systems i.e., biotrans-
formation, resting cell and in vitro (microsome) systems 
[44]. Though in vitro studies are precise, the purification 
and enzyme reaction with microsomes is rather intricate 
and sophisticated due to the technical difficulties associ-
ated with the isolation of active microsomal protein [15] 
Apparently, whole-cell-biotransformations of recombi-
nant yeasts are often more feasible owing to its simplicity, 
enzyme stability, and efficient biotransformation [77, 81].
Construction of cDNA libraries in S. cerevisiae is a 
promising strategy to develop a rapid functional screen-
ing system of multiple fungal CYPs. Functionomic 
studies carried out with 425 CYP isoforms from P. 
chrysosporium (120 CYPs), P. placenta (184 CYPs), and 
A. oryzae (121 CYPs) using S. cerevisiae CPR resulted 
in the discovery of several CYPs with novel catalytic 
potentials (Fig.  4) [18, 82]. Since the functional activ-
ity of the majority of fungal CYPs remains unclear and 
information regarding sequence-function relationships 
is limited, this specific screening system is certainly a 
competent approach to identify potential CYPs. Com-
prehensive functional screening of the P. chrysosporium 
CYP library facilitated the identification of a series of 
CYPs reactive towards seven petrochemicals, three 
plant-related compounds, three pharmacochemicals, 
three chlorinated dibenzo-p-dioxins, and two steroi-
dal compounds [83]. Using the P. placenta CYP library, 
the active CYPs reactive towards 11 compounds, such 
as dehydroabietic acid, pyrene, and trans-stilbene were 
identified [40]. Furthermore, active CYPs from A. oryzae 
reactive towards 7-ethoxycoumarin, genistein, narin-
genin, testosterone, dehydroabietic acid, and diclofenac 
were also identified [50]. Construction and compilation 
of cDNA libraries is thus an efficient and effective strat-
egy that allows rapid functional screening with ease in 
culturing several yeast transformants and prompt bio-
conversions. Nevertheless, construction of a full-length 
CYP library of a whole fungal CYPome is complex and 
laborious; this robust functional screening approach has 
proved successful and facilitated identification of sev-
eral novel CYPs without prior information about their 
sequence-structure–function relationships.
However, there are some exceptions and all the cloned 
fungal CYPs may not necessarily express well in S. cer-
evisiae. For instance, among 120 CYP genes from P. chr-
sosporium, only 70 CYPs were successfully expressed 
based on a carbon monoxide binding assay [83]. Alter-
natively, unconventional non-Saccharomyces yeasts such 
as methylotrophic yeast Pichia pastoris [84], fission yeast 
Schizosaccharomyces pombe [85], dimorphic yeasts Yar-
rowia lipolytica [86] and Arxula adeninivorans [87], 
lactose-utilizing yeast Kluyveromyces lactis [88] and 
its thermophilic sister strain K. marxianus [88] can be 
employed to overcome the restrictions associated with 
heterologous CYP expression. For example, the expres-
sion of P. chrysosporium redox enzyme systems and CYPs 
(CYP5136A3, CYP63A2) in P. pastoris enhanced active 
form of functional expression [53, 89]. Interestingly, com-
parative heterologous expression and biotransformation 
studies of CYP505A1, a self-sufficient fungal CYP, was 
examined using a broad-range common vector (pKM118) 
system; A. adeninivorans, Y. lipolytica, and K. marxi-
anus exhibited activity (in order from highest to lowest), 
whereas S. cerevisiae showed no CYP505A1 activity [87]. 
These results suggest that the expression host should 
be carefully evaluated to permit the efficient functional 
characterization of membrane-bound fungal CYPs.
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Expression of fungal CYPs in fungal host systems
Biotransformation using fungal whole cells is a simple, 
low-cost, and time-saving system, thereby enabling direct 
and industrial-grade biocatalysis [90]. Several fungal 
conversions such as the hydroxylation of progesterone 
into 11α-hydroxyprogesterone in Rhizopus spp. and the 
11β-hydroxylation of deoxycortisol in Curvularia spp. 
have indicated the commercial potential of fungal whole 
cell-based biocatalysis [1, 54]. Interestingly, filamen-
tous fungi have emerged as a desirable expression host, 
especially for the large-scale production of pharmaceu-
tically relevant homologous and heterologous proteins 
[91]. Although the manipulation of DNA in fungi is 
relatively complex, the fungal host systems offer proper 
maturation of mRNA precursors (splicing), which is 
rather difficult for other recombinant hosts (bacteria or 
yeast). In addition, fungal host system offers a platform 
for the eukaryotic-style post-translational modifica-
tion of proteins because of its efficient protein secretion 
machinery [91–93]. However, as the secretory yields 
Fig. 4 Catalytic potentials of fungal CYPs identified through functional screening. Representative examples of CYPs from P. chrsosporium, A. oryzae 
and P. placenta are presented in black, blue and red, respectively. The CYP names are denoted excluding “CYP”. For example, CYP512C1 is abbreviated 
as 512C1
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of heterologous proteins are comparatively lower than 
homologous proteins, various strategies were attempted 
to improve the recombinant protein production [92]. 
Interestingly, codon optimization prevents the prema-
ture polyadenylation and stabilizes the gene transcripts 
of heterologous genes for enhanced expression in fungal 
host system [92]. The membrane-bound benzoate para 
hydroxylase, CYP53A1 and its redox partner, NADPH 
reductase from the filamentous fungus Aspergillus niger 
was overexpressed in the recombinant A. niger strain 
and functionally characterized using fungal microsomes 
(Table 2) [94]. In the fungal quadruple auxotrophic host 
Aspergillus oryzae, the whole gene cluster, including 
geranylgeranyl diphosphate synthase, terpene synthase, 
and two CYPs (PbP450-1 and PbP450-2) was introduced 
for the biosynthesis of diterpene aphidicolin [95]. Like-
wise, controlled expression of tenellin biosynthetic gene 
cluster including two fungal CYPs (tenA and tenB) from 
Beauveria bassiana was performed in the heterologous 
host A. oryzae [96]. Herein, replacing the promotors with 
heterologous amyB inducible promoter not only solved 
the transcriptional activation issues, but also significantly 
enhanced the productivity of tenellin (243  mg/L) over 
five times compared to its native host (47.3  mg/L) [96]. 
Alternatively, genetic engineering or manipulations of 
fungal gene clusters may facilitate the production of new 
secondary metabolite products. Expression of the hybrid 
polyketide synthetases in A. oryzae generated by rational 
domain swaps coupled with co-expression of CYP (tenA 
and tenB) genes facilitated resurrection of the extinct 
metabolite bassianin [97].
Significance of CPR in fungal CYP‑mediated 
reactions
Cytochrome P450 reductase, the membrane-bound difla-
vin electron donor protein, is crucial for CYP mediated 
reactions as it is responsible for the sequential delivery of 
two electrons for the activation of molecular oxygen in 
the class II system [29]. CPR has evolved as a fusion of 
two ancestral proteins in which the N-terminal domain 
is homologous with the bacterial flavodoxins containing 
FMN, while the C-terminal region is homologous with 
the ferredoxin NADP+ reductase and the NADH-Cyt 
b5 reductase containing FAD [16, 29]. In addition to the 
abundance of CYP, the efficacy of monooxygenase reac-
tions also relies on the abundance and electron transfer 
compatibility of its redox protein partner [77, 98]. Appar-
ently, compared to their larger and diverse CYPomes, 
most fungi possess only one or two CPRs, with an excep-
tion of four putative CPRs in F. oxysporum [Table 1] [38, 
67, 78]. Although, the biological roles of multiple CPR 
paralogs in fungi remains unclear; it is evident that the 
functional role of each CPR is different [47, 67, 78]. It 
has been hypothesized that that CPR1 is responsible for 
CYPs during endogenous primary metabolism; while 
CPR2 possibly functions in secondary metabolism (xeno-
biotic detoxification) [47, 67]. The plant pathogenic fun-
gus Cochliobolus lunatus possesses two reductases, CPR1 
and CPR2; both supported CYP activity, whilst with dif-
ferent product specificities [67]. In the presence of CPR1, 
CYP53A15 converted benzoic acid (BA) to 4-hydroxy-
benzoic acid and 3-methoxybenzoic acid (3-MBA) to 
3-hydroxybenzoic acid (3-HBA). However with CPR2, 
the same enzyme converted both of the substrates to 
3,4-dihydroxybenzoic acid through two step oxidations 
[67]. Likewise in the fungus G. clavigera, both the CPRs 
reduced cytochrome C and performed hydroxylation of 
oleic acid with CYP630B18; but the catalytic efficiency is 
much higher with CPR2 than with CPR1 [47].
Although fungal CYPs can show activity with heterolo-
gous CPR [40, 50, 83]; recent reports elucidated that the 
electron transfer compatibility and coupling efficiency of 
homologous CYP-CPR interactions are relatively higher 
[38, 77, 99]. The catalytic efficiency and substrate speci-
ficity of fungal CYPs was significantly influenced and 
altered by the source of reductase [38]. For instance, 
CYP53A19 of F. oxysporum was reactive towards BA and 
3-MBA in the presence of S. cerevisiae CPR; whereas it 
only converted BA with C. albicans CPR [38]. Remark-
ably, CYP53A19 with its homologous F. oxysporum 
CPR not only increased the conversion rates of BA and 
3-MBA, but also exhibited activity towards 3-HBA [38]. 
Similarly, F. oxysporum ɷ-hydroxylase CYPs, CYP539A7 
and CYP655C2, produced higher yields with its homolo-
gous redox partner compared to the heterologous partner 
[41]. As the interactions with CPR also play a major role 
in the outcome of CYP reactions, selection of an appro-
priate functional CPR is crucial to achieve optimal CYP 
activity. However, the underlying mechanism behind 
how CPRs affects substrate specificity beyond catalytic 
efficiency remains unclear. Hitherto, CPRs are perceived 
as highly conserved redox systems with not much room 
for functional or organismal diversity. Henceforth, much 
more attention, should be focused on CPR to enhance 
the catalytic efficiency and even to alter the substrate 
specificity of CYP-mediated reactions.
Overcoming limitations and future perspectives
Although fungal CYPs have extensive potentials they 
suffer from certain limitations/challenges obstruct-
ing their viable applications. The general bottlenecks in 
industrial applications of CYPs are lack of stability, low 
activity, poor expression levels, limited solvent toler-
ance, expensive cofactor requirements, electron supply, 
and uncoupling between NAD(P)H oxidation and prod-
uct formation [1, 100]. Considering the extraordinary 
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potential of CYPs, several reviews have addressed their 
limitations and have focused on tackling these challenges 
to promote CYPs as robust biocatalysts [1, 3, 9, 10, 100]. 
Fungal CYPs also inherently possess the same limita-
tions; and recent advancements has sought to overcome 
the major hurdles posed by fungal CYPs [1, 12]. Devel-
opment of modern tools of biotechnology offers a wide 
scope in the protein discovery, structure prediction and 
enzyme engineering for the improvement of biocatalysts 
and their tailor-designed integration into the industrial 
processes. Enzyme engineering through mutagenesis 
is one of the tools to modify fungal CYPs as sustainable 
catalysts by solving issues concerning low expression 
levels and poor activity [1, 3, 10, 100]. For example, the 
oxidizing activity of the P. chrysosporium PAH oxidase 
(CYP5136A3) was significantly improved by a rational 
designing approach through site-directed mutagenesis 
[101]. In A. terreus, the expression levels of non-opti-
mized LovA enzyme was very low and not detected in the 
immunoblot analysis using FLAG antibodies [61]. How-
ever, engineering of LovA through synthetic codon opti-
mization and/or N-terminal peptide replacement from 
lettuce CYP markedly increased the expression levels in 
S. cerevisiae [61]. Interestingly, thermostable fungal CYPs 
from the thermophilic biomass-degrading fungi Myceli-
ophthora thermophila and Thielavia terrestris identified 
using bioinformatic tools showed high thermal tolerance 
and in vitro stability based on calculated protein melting 
temperature and instability index [102]. Although further 
experimental characterization is necessary, such ther-
mostable fungal CYPs can be used for industrial applica-
tions, and structural analysis may pave a way to enhance 
the stability of mesophilic CYP enzymes.
Remarkable achievements and strategies have been 
developed for several mammalian and plant CYPs 
to overcome these limitations [1, 6, 12]. The same 
approaches can also be applied to fungal CYPs to 
improve their functional properties. As the catalytic 
activity of CYPs is dependent on NAD(P)H and reduc-
tase, constant supply of electrons is crucial to enhance 
the efficiency of monooxygenases reactions. To sur-
mount the electron dependence of fungal CYPs, con-
struction of chimeric CYP-CPR fusion constructs or 
optimization of the redox chain can be effective. Artifi-
cial CYP-CPR fusion constructs termed “Molecular lego” 
are a competent startegy for comparative analysis of dif-
ferential redox partners to find the optimal redox system 
[103, 104]. In addition, improved intracellular electron 
recycling can be obtained through cofactor regeneration 
by coexpressing CYPs along with glucose/formate dehy-
drogenase or aldehyde reductase [105]. Besides, alterna-
tive approaches such as surrogate oxygen atom donors, 
as well as enzymatic, direct chemical, electrochemical, 
photochemical and light driven cofactor-free reduction 
system, can also be employed [103, 106, 107]. Interest-
ingly, immobilization of CYPs and their redox partners 
on nanodiscs is also a successful attempt in overcoming 
limitations in the assembly of CYP components [108]. 
Incorporation of membrane bound CYPs in nanodiscs 
enables stable, soluble, homogenous and monomeric 
preparations in native-like lipid bilayer environments 
thereby preventing aggregation and inactivation [108]. 
Furthermore, metabolic engineering of expression hosts 
are performed by knocking out competing pathways to 
enhance the yield of CYP-mediated biocatalysis. Engi-
neering of the C. tropicalis genome by eliminating 16 
undesirable genes comprising 6 CYPs, 4 fatty alcohol 
oxidases, and 6 alcohol dehydrogenases enabled effec-
tive production of ω-hydroxy fatty acids [43]. Likewise, 
construction of β-oxidation pathway inactivated (ΔPox1) 
S. cerevisiae mutant by disrupting the acyl-CoA oxidase 
enzyme has also proven successful for fungal CYP medi-
ated biotransformations [41]. Remarkably, CYPs also 
play key roles in synthetic biology for the production of 
highly valuable compounds; development of the antima-
larial drug artemisinin by engineering CYP71AV1 from 
Artemisia annua in yeast was certainly a ground-break-
ing achievement [6, 109]. Although plant, mammalian, 
and bacterial CYPs are currently focused in synthetic 
biological studies, fungal CYPs will soon progress as a 
cynosure due to their outstanding functional diversity.
Conclusion
This review summarizes the recent developments in 
the study of fungal CYP systems and elaborates on their 
novel catalytic properties. Realization of the versatile bio-
catalytic potentials and applications of fungal CYPs has 
led to the discovery of many novel enzymes. With the 
plethora of functional diversity and magnificent catalytic 
potentials, fungal CYPs have emerged as versatile biocat-
alytic enzymes. Nevertheless, a multitude of fungal CYPs 
remain unexplored and unexploited. Overcoming cur-
rent challenges with the advent of modern biology and a 
better understanding of genome-structure-functionomic 
analysis will certainly open the window for various sig-
nificant applications.
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